

## Comment on: “Modern management of seizures and epilepsy”

Dirk Körschenhausen

MARAS AG, Compliance officer on behalf of UCB Pharma AG

In the Swiss Medical Weekly, an article written by Prof. Margitta Seck and Dr Markus Gschwind (University Hospital of Geneva, Switzerland) with the title “Modern management of seizures and epilepsy” has been published [1].

In table 5 of the published article, where the main features of the drugs are summarised, the prices for a daily dose are also listed. According to the information in the published table, Fycompa® (perampanel) is cheaper than Vimpat® (lacosamide). The price of Vimpat is given as 9.6 CHF/day, based on a dosage of 300 mg/day, and the price of Fycompa as 8.4 CHF/day at the (most frequent) daily dose of 8 mg.

In contrast to the statements made by the authors of the article in the published table, and taking into account the most-used pack and the defined daily dose (DDD; source: WHOCC ATC/DDD index) of these two products, the price of Fycompa® (ex-factory price or public price) per DDD is always greater than that of Vimpat®! You can find the correct numbers in table 1.

May we therefore kindly ask you to correct the statement that Fycompa is less costly than Vimpat? This message is the direct opposite of the true situation and might be a significant commercial drawback for our company.

**Table 1:** Fycompa and Vimpat price (source: Spezialitätenliste (SL) <https://bag.e-mediat.net/SL2007.Web.External/ShowPreparations.aspx>)

Product	Molecule	Pack size	FAP-PF (CHF)	PP (CHF)	DDD	Dosage	FAP-PF/DDD (CHF)	Variation FAP-PF/DDD*	PP/DDD (CHF)	Variation PP/DDD*
Fycompa	Perampanel	8 mg 28 tabs	190.33	234.90	8 mg/day	1 tab/day	6.80	12.89%	8.39	11.88%
Vimpat	Lacosamide	150 mg 56 tabs	168.6	209.95	300 mg/day	2 tabs/day	6.02		7.50	

\* Fycoma vs Vimpat

Correspondence:  
Dirk Körschenhausen, MD  
Director Medical and Regulatory Affairs / CEO  
MARAS AG  
Alte Steinhäuserstrasse 21  
CH-6330 Cham  
[dirk.koerschenhausen\[at\]ucb.com](mailto:dirk.koerschenhausen[at]ucb.com)

### Reference

- Gschwind M, Seck M. Modern management of seizures and epilepsy. Swiss Med Wkly. 2016;146:w14310. doi:10.4414/smw.2016.14310. [PubMed](#)